Maria Collazo-Clavell, MD,
Endocrinologist, Division of Endocrinology, Diabetes, Metabolism & Nutrition, Mayo Clinic; Associate Professor, Mayo College of Medicine
Nearly 20% of Medicare beneficiaries are readmitted within 30 days of hospital discharge--resulting in over $15 billion in annual costs. Yet, between 10 to 50% of readmissions are avoidable. Learn how the Transitional Care Model (TCM) targets the individual, family and system drivers of readmission and why it is being adopted by organizations including Aetna and Kaiser Permanente.
- Discuss recent controversies surrounding DM2 management
- Identify HgbA1c, blood pressure and lipid management goals
- List third treatment options when metformin and sulfonylurea are insufficient
- Describe the role of incretin therapy in DM2 management
Dr. Maria Collazo-Clavell is board certified in internal medicine, endocrinology, diabetes and metabolism. She is a consultant in the Division of Endocrinology, Diabetes, Metabolism & Nutrition at Mayo Clinic and an associate professor at Mayo Clinic College of Medicine. The Aibonito, Puerto Rico, native has been with Mayo Clinic since 1994. She is a member of the American Association of Clinical Endocrinologists, the American College of Endocrinology, the American Diabetes Association and The Endocrine Society. Dr. Collazo-Clavell is medical editor for diabetes content on the Mayo Clinic web site, as well as the book "Mayo Clinic on Managing Diabetes." Her clinical interests include management of type 1 and type 2 diabetes, obesity and nutritional disorders.